Kwo Elizabeth sold $97K of KMTS

Kwo Elizabeth sold 4,010 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $24.26 on 2026-09-21.

Original reporting
SEC EDGAR · Kwo Elizabeth
Published Sep 23, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
high confidence
Mentioned
$KMTS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The sale is small and unlikely to affect KMTS stock price materially.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions not disclosed in the filing.

Relevance 3/10Novelty 3/10Timing: filing date 2026-09-21

Background

Form 4 filings disclose insider transactions; this filing reports a director's sale.

Company-level read

Ticker impact

$KMTSNeutralHigh confidence
Context

Director Kwo Elizabeth sold 4,010 shares for $97,267, reducing her stake to 14,116 shares.

Expected impact

No material price movement expected.

Evidence & confidence

The transaction amount is small relative to market cap and does not change control.

Market effects

None significant for the medical device sector.

No regional impact.

Limited to investors tracking insider activity.

Counterpoint

The sale could be unrelated to company fundamentals and merely personal liquidity.

Key entities

  • Kwo Elizabeth

    Director of KESTRA MEDICAL TECHNOLOGIES, LTD.

  • KMTS

    KestrA Medical Technologies, listed on Nasdaq.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.